CAS: 100-92-5; N,2-Dimethyl-1-Phenylpropan-2-Amine

上下游产品

β-Hydroxymephentermin N-(2-methyl-1-phenylpropan-2-yl)-1-phenylmethanimine methyl iodide oxethazaine(2-cyclohexyl-1,1-dimethyl-ethyl)-methyl-amine chloro-acetic acid-[(1,1-dimethyl-2-phenyl-ethyl)-methyl-amide] N-Hydroxy-mephentermin Formyl(N,α,α-trimethyl)phenylethylamin

📜β-Hydroxymephentermin置于氯化亚砜体系中,化学反应生成美芬丁胺
参考文献:Us2597445
标题:Us2597445

专利信息

专利号:US-11717498-B2
优先权日:2013-12-31
标题 :Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms
发明人：POPP KARL; MECKLER HAROLD
权利人:Chemapotheca LLC; PHARMAPOTHECA A INC
摘要:The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

专利号:US-6153615-A
优先权日:1991-12-26
标 题 :Blocking induction of tetrahydrobioterin to block induction of nitric oxide synthesis
发明人：GROSS STEVEN S
权利人:CORNELL RES FOUNDATION INC
摘要:Guanosine triphosphate pathway tetrahydrobiopterin synthesis antagonist and/or pterin salvage pathway tetrahydrobiopterin synthesis antagonists are administered to inhibit nitric oxide synthesis from arginine in vascular cells in a subject in need of such inhibition (e.g., for prophylactic or curative effect for endotoxin- or cytokine-induced hypotension or for restoration of vascular contractile sensitivity to pressor agents in the treatment of such hypotension). The tetrahydrobiopterin synthesis antagonist may be administered with α 1 -adrenergic agonist or with nitric oxide synthase inhibitor. The tetrahydrobiopterin synthesis antagonists are also administered to attenuate inflammation caused by induced nitric oxide production in immune cells. Unwanted counterproductive or side effects can be eliminated or ameliorated by administration additionally of levodopa with or without carbidopa and L-5-hydroxytryptophane.

专利号:US-5874433-A
优先权日:1993-11-29
标题 :Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
发明人：GROSS STEVEN S
权利人:CORNELL RES FOUNDATION INC
摘要:Inhibitor of the use of tetrahydrobiopterin as a cofactor for nitric oxide synthase, e.g., substituted 4-phenyl(hydropyridines) such as 1-methyl-4-(3',4'-dihydroxyphenyl)-1,2,3,6-tetrahydropyridine or, 4-(3',4'-dihydroxyphenyl)-1,2,3,6-tetrahydropyridine) or tetrahydropterin analog which does not replace tetrahydrobiopterin as a substrate for nitric oxide synthase such as (6R,S)-6,7-dimethyl-tetrahydropterin or (6R,S)-tetrahydrofolic acid or 2,4-diamino-, 2,6-diamino, or 4,6-diamino mono- or disubstituted pyrimidines or the corresponding pyrimidine-3-oxides such as 2,4-diamino-6-(diethylamino)pyrimidine, 2,4-diamino-6-piperidino-pyrimidine-3-oxide, 2,4-diamino-6-hydroxypyrimidine, 4,6-diamino-2-hydroxypyrimidine or 2,5-diamino-4,6-dihydroxypyrimidine is administered to inhibit nitric oxide synthesis from arginine in vascular cells in a subject in need of such inhibition (e.g., for prophylaxis or treatment of cytokine- or endotoxin-induced hypotension (e.g., septic shock). The latter two types are advantageously administered with nitric oxide synthase inhibitors (concurrent therapy) or to potentiate the effect of α 1 -adrenergic agonists in the prophylaxis or treatment of induced hypotension.

专利号:US-5216025-A
优先权日:1989-09-13
标题 :Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
发明人：GROSS STEVEN S; KILBOURN ROBERT G; LEVI ROBERTO
权利人:UNIV TEXAS; CORNELL RES FOUNDATION INC
摘要:A method for treatment of an animal for systemic hypotension induced by internal nitric oxide production caused by endotoxin or cytokines. The method involves administering an α 1 adrenergic agonist and an amount of an inhibitor of nitric oxide formation from argi n Research relating to the development of this invention was supported by the United States Public Health Service grants which gives the United States government certain rights to use of the present invention.

专利号:US-4474703-A
优先权日:1976-11-09
标 题 :Grignard reagents and processes for making and using them
发明人：BUJADOUX KAREL; NEYER JEAN-MARIE; HOUZEAUX JEAN-PIERRE
权利人:CHARBONNAGES STE CHIMIQUE
摘要:An organometallic halide having the formula: (RMX) (MX2)a(MR2)b (MH2)c wherein a
专利号:US-7078406-B2
优先权日:2001-10-09
标 题 :Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
发明人：CARVER JR THEODORE E; RINKER JAMES M
权利人:JOHNSON & JOHNSON PHARM RES
摘要:The present invention is directed to a compound of Formula I: n nwherein A, R 1 , and R 2 are defined herein. The present invention is also directed to compositions comprising compounds of Formula I, methods of using compounds of Formula I, and methods of making compounds of Formula I.